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Metal-based imaging agents: progress towards
interrogating neurodegenerative disease
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Central nervous system (CNS) neurodegeneration is defined by a complex series of pathological processes
that ultimately lead to death. The precise etiology of these disorders remains unknown. Recent efforts show
that a mechanistic understanding of the malfunctions underpinning disease progression will prove requisite
in developing new treatments and cures. Transition metals and lanthanide ions display unique characteristics
(i.e., magnetism, radioactivity, and luminescence), often with biological relevance, allowing for direct
application in CNS focused imaging modalities. These techniques include positron emission tomography
(PET), single-photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), and
luminescent-based imaging (LumI). In this Tutorial Review, we have aimed to highlight the various metal-
based imaging techniques developed in the effort to understand the pathophysiological processes
associated with neurodegeneration. Each section has been divided so as to include an introduction to the
particular imaging technique in question. This is then followed by a summary of key demonstrations that
have enabled visualization of a specific neuropathological biomarker. These strategies have either exploited
the high binding affinity of a receptor for its corresponding biomarker or a specific molecular transformation
caused by a target species, all of which produce a concomitant change in diagnostic signal. Advantages
and disadvantages of each method with perspectives on the utility of molecular imaging agents for
understanding the complexities of neurodegenerative disease are discussed.
Key learning points
(1) The importance of molecular imaging for the understanding of neurodegenerative disease
(2) To understand the importance of a specific metal in each imaging modality
(3) The strategies to design an effective metal-based molecular imaging agent
(4) Current limitations of each imaging modality
(5) Future perspectives
Introduction
Central Nervous System (CNS) degeneration involves a series of
neurological conditions that affect millions of people world-
wide. These diseases stem from the progressive dysfunction
and death of neuronal cells, which lead to loss of motor
function and memory. A common theme amongst neurodegen-
erative processes is the progressive misfolding, aggregation,
and accumulation of protein and peptide aggregates resulting
in cellular dysfunction, loss of synaptic connections, and brain
damage. The most common disorders, Alzheimer’s disease
(AD), Parkinson’s disease (PD), Huntington’s disease (HD),
Lewy Body dementia, prion diseases, and amyotrophic lateral
sclerosis (ALS), also share phenotypic similarities and all result
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in death.1 Current treatment protocols offer short-term pallia-
tive benefits with no long-term improvement for patients or
relief for caregivers. Not surprisingly, the pharmaceutical
industry and academic institutions alike are seeking to develop
new therapies, as well as working to elucidate the biochemical
processes responsible for these disorders. High attrition rates
in clinical trials have led to the belief that understanding the
precise etiology of CNS disease is critical to developing an
effective treatment or cure. As discussed below, metal-based
imaging modalities may have a critical role to play in this
search. The goal of this tutorial review is to summarize recent
progress in the area.
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To date, a variety of metal-based approaches have proved
useful in illuminating the biochemical malfunctions that lead
to neurodegeneration. These methods include: (1) positron
emission tomography (PET), (2) single-photon emission com-
puted tomography (SPECT), (3) magnetic resonance imaging
(MRI), and (4) luminescent imaging. This tutorial review will
highlight metal-based imaging techniques used to understand
aberrant biochemical processes involved in neurodegenerative
diseases. Particular focus will be placed on a general overview of each
imaging technique, the purpose of each method, and its implemen-
tation by highlighting recent demonstrations in the literature.
Positron emission tomography (PET) &
single photon emission computed
tomography (SPECT)
Major advances in scanner technology over the last 20 years
have facilitated adoption of PET and SPECT in the biomedical-
imaging field. PET/SPECT-based imaging requires the use of
a radiopharmaceutical or radiotracer. Typically, this is a mole-
cule containing a radioisotope within its structure. For PET, the
radiotracer contains a positron-emitting isotope. The emitted
positron (b+) or ‘‘anti-electron’’ collides with nearby electrons
resulting in an annihilation process that produces two g-rays at
exactly 511 keV emitted 1801 apart. The specific energy of these
g-rays is dissimilar to other modes of decay possible for most
radionuclides. The PET derived g-rays (511 keV) are detected
by specialized instrumentation and used to form the image
for diagnosis. SPECT utilizes a similar approach wherein the
radiotracer contains a g-ray emitting short-lived isotope (ideal
g-ray energies: 100–250 keV), which is detected to provide the
image for diagnosis. The required dosage for PET/SPECT is
commonly within picomolar (pM; 1012 mol L1) to nanomolar
(nM; 109 mol L1) concentrations reducing any potential
toxicology risk arising from radioactive isotope and non-
radioactive ‘‘carrier’’ material.
The requirement for highly specialized and expensive instru-
ments had previously limited the widespread adoption of PET.
Due to early adoption and cheaper instrumentation, more
hospitals are equipped with SPECT scanners. As a result, SPECT
is more widespread, both in terms of clinical use and current
imaging research. However, modern PET setups permit remark-
able sensitivity compared to the analogous magnetic resonance
imaging (MRI) and X-ray computer tomography (CT) approach,
and arguably provides a slight advantage over SPECT-based
methods. This has resulted in a shift towards PET-based
technology in recent years.
For a PET-based imaging agent to achieve the spatial resolu-
tion needed for use in neurological or small animal imaging, a
radioisotope with low energy positron emissions is required.
The use of such isotopes enables the production of higher
resolution images, i.e., lower positron energies correlate to a
shorter positron distance giving a more specific location.
Tables 1 and 2 highlight the current radioisotopes that have
been used towards the development of radiotracers for PET/
SPECT imaging in neurodegenerative diseases with corres-
ponding decay energies, half-lives, and production methods.
It is important to note, each radioisotope may be subject to one
or more decay modes; this can require additional consideration
when designing a PET/SPECT radiotracer. The reader is direc-
ted to an excellent review by Blower for a more extensive list of
radioisotopes used in medical imaging and therapy.2
The PET/SPECT-based imaging section will be divided
according to each metal-based radioisotope with attendant
consideration of the neurodegenerative disease-related biomarker
target. For use of other radioisotopes and non-metal-basedXiao-Peng He
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systems for PET/SPECT-based imaging and therapy the reader
is directed to a number of excellent reviews.2,4
The development of metal-based radiotracers requires knowl-
edge of metal coordination chemistry and appropriate ligand
design. Moreover, the radiotracer itself must:
 Have a high selectivity and binding affinity for the desired
target with rapid binding kinetics.
 Target a specific receptor or biochemical process occurring
in sufficient concentration so as to provide a good signal-to-
noise ratio.
 Permit rapid insertion of the metal radioisotope and
produce a complex that does not result in the loss of binding
affinity to the biological target. Protocols that allow for metal
complexation in aqueous conditions are particularly desired
since they may allow for the facile development of ‘‘kit-based
technology’’ for use in a clinical setting.
 The imaging agent or administration technique must
allow for sufficient localization within the brain, i.e., penetrate
the blood brain barrier (BBB). This remains a challenge when
designing CNS agents.
Copper (60Cu, 61Cu, 62Cu, 64Cu) – PET
Copper (Cu) has two key biologically relevant oxidation states,
Cu+ and Cu2+. Several decades of research from the inorganic
chemistry community have resulted in a number of effective
chelators able to form stable complexes with both Cu oxidation
states. The imaging community has largely relied on Cu2+ systems
containing mixed donors (e.g., N and S) with coordination
numbers (CNs) of 4–6. To date, a number of Cu positron-
emitting isotopes have found utility in PET-based imaging.
These include: 60Cu (t1/2 = 20 min),
62Cu (t1/2 = 9.7 min),
61Cu
(t1/2 = 3.4 h), and
64Cu (t1/2 = 12.7 h). Copper-62 is an attractive
option despite having a relatively short half-life (t1/2 = 9.7 min)
as it can be readily produced via an on-site generator.
In contrast, the other Cu isotopes are currently produced from
solid targets at cyclotron facilities. Copper-64 (t1/2 = 12.7 h) has
a longer half-life and has been used extensively to radiolabel a
range of small molecules, antibodies, proteins, and nanoparticles.5
The low energy positron emission of 64Cu also enables the produc-
tion of high-quality images comparable to the gold standard
18F PET (Table 1). To date, [18F]FDG (2-[18F]fluoro-2-deoxy-D-
glucose) is the only PET imaging agent that has seen widespread
clinical use. It has been extensively used as an imaging agent
for studying glucose metabolism in the brain and identifying
potential neurological disorders through reduced glucose
usage.4 In the following section, we have highlighted select
strategies implementing the Cu2+ radioisotopes for the imaging
of neurodegenerative disease-related biomarkers. The reader is
also directed to an excellent review by Cui and co-workers for
more examples of Cu2+-based radiotracers explored in the
context of neurodegenerative disease.5
To be viable as clinical candidates, metal-based imaging
agents must have the appropriate physicochemical properties
(e.g., log P) so as to balance the need for cell permeability and
water solubility. Optimizing this features often requires planned
synthetic efforts and an ability to derivatize easily the core metal-
chelating scaffold. Early efforts to develop Cu-based PET agents
focused on square planar metal complexes, particularly
Cu(II)(diacetyl-bis(N4-methylthiosemicarbazone)) [Cu2+(atsm)] and
Cu(II)(glyoxal-bis(N4-methyl-3-thiosemicarbazonato)) [Cu2+(gtsm)]
(Fig. 1).
Seminal efforts by Yokoyama and co-workers demonstrated
that Cu(II)(diacetyl-bis(N4-methylthiosemicarbazone)) Cu(atsm)
can be utilized as a PET radiotracer for the imaging of hypoxia
in brain and neck cancers.6 Cu(atsm) displayed good stability
and blood brain barrier (BBB) permeability with attendant
accumulation in regions of the brain suffering from oxidative
stress. Under these latter conditions, Cu(atsm) was found to
undergo a superoxide oxidase-type conversion wherein super-
oxide (O2
) is oxidized to molecular oxygen (O2) and the Cu
2+
center is reduced to Cu+.7 Taking advantage of this redox
chemistry, Yoneda and co-workers applied 62Cu(atsm) to image
the striatum brain region (i.e., the motor and reward system) in
patients with Parkinson’s disease (PD).6 High accumulation
of 62Cu(atsm) was seen in the striatum of the PD patients
compared to the cerebral cortex. This finding was considered
consistent with a localized enhancement of oxidative stress due
to an increased concentration of superoxide. These efforts by
Yoneda and associates are credited with inspiring further
imaging research targeting the aberrant oxidative and nitrative
processes associated with neurodegeneration.
Fig. 1 Cu-Based PET agents – Cu(II)(diacetyl-bis(N4-
methylthiosemicarbazone)) [Cu(atsm)] and Cu(II)(glyoxal-bis(N4-methyl-
3-thiosemicarbazonato)) [Cu(gtsm)].
Table 1 Radioisotopes currently used in PET-based imaging of neurode-
generative disease related biomarkers3
Radio-
isotope t1/2
Production
methods
Energy
(b+) – MeV
Energy
(g) – MeV
Decay
type
11C 20 min Cyclotron 1.0 — b+
18F 110 min Cyclotron 0.6 — b+
62Cu 9.7 min 62Zn/62Cu
generator
2.9 0.12 b+/g
64Cu 12.7 h Cyclotron 0.7 0.13 b+, b, g, EC
68Ga 1.1 h 68Ge/68Ga
generator
1.9 0.11 b+, g, EC
89Zr 78.5 h Cyclotron 0.9 — b+, EC
Table 2 Current radioisotopes used in SPECT-based imaging towards
neurodegenerative disease related biomarkers
Radioisotope t1/2 (h) Production methods g-ray – keV Decay type
99mTc 6 99mTc/99Mo generator 141 g
123I 13 Cyclotron 159 g, EC
111In 67.9 Cyclotron 245 g, EC
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Continued interest in Cu2+ systems has provided an impetus
to develop Cu(atsm) analogues with stimuli-specific properties.
Blower and co-workers recently developed an elegant method
utilizing Cu(gtsm), the more easily reduced variant of Cu(atsm).8
The use of a glyoxal backbone, as found in gtsm, instead of the
diacetyl in atsm, increased the reduction potential of the coor-
dinated Cu2+ making it more susceptible towards intracellular
reduction; E1/2 = 0.44 mV versus Ag/AgCl for Cu(gtsm) com-
pared to E1/2 = 0.60 mV versus Ag/AgCl for Cu(atsm).9 In these
studies, it was proposed that the Cu(gtsm) complex passes
first through the cell membrane via a combination of passive
diffusion and protein-carrier mechanisms. Subsequently, the
Cu(gtsm) complex disassociates to yield free Cu+ (Scheme 1).
In strictly operational terms, these efforts allowed for the PET-
based imaging of free Cu+ ions in a transgenic AD mouse model
and an initial assessment of the potential of Cu(gtsm) to act as a
useful diagnostic biomarker.9
Notably, 64Cu(gtsm) was able to penetrate the BBB and
increase 64Cu concentrations in the brain. PET imaging
revealed statistically significant differences in 64Cu global brain
uptake and clearance, as well as in the brain regional 64Cu
concentration between AD transgenic mice and age-matched
controls.8 These findings were among the first to show that
64Cu could be used as an imaging tool to track changes in the
trafficking of free Cu ions in the context of neurodegenerative
disease studies.
Free metal ions, such as Cu2+, Fe2+/3+, Mg2+, Mn2+, and Zn2+,
are known to induce aggregation of amyloid-beta (Ab) peptide
and support formation of Ab plaques, a key pathological
biomarker of AD.10 Imaging tools enabling the detection
of Ab aggregates are thus of great interest for understanding
AD progression. Non-metal based PET imaging of Ab plaques
is possible through the use of radiolabelled benzothiazole
and stilbene derivatives, [18F]florbetapir, [18F]flutemetamol,
and [18F]florbetaben (Fig. 2).5,11 However, 18F radiotracers (as
well as those based on 11C) have a number of disadvantages,
such as relatively short half-lives ([18F] t1/2 = 110 min; [
11C] t1/2 =
20 min) that require late stage synthetic incorporation of
the radiolabel, which is typically produced on site in highly
specialized facilities. The development of metal-based strate-
gies that rely on longer lived radionuclides and the insertion
of a metal radioisotope into a ligand-conjugate structure with a
predetermined high target affinity and selectivity are thus
attractive.
Donnelly and co-workers have recently reported an elegant
demonstration of 64Cu-based PET imaging of Ab plaques. They
did this by coupling the Ab targeting motifs, benzothiazole and
dimethylaminostyrenyl, to Cu(atsm) to generate complexes
CuL1–CuL3 (Fig. 3).
11 The resultant complexes proved stable
in aqueous solutions over a range of pH and avoided the
unwanted release of Cu. The authors noted that CuL1 displayed
poor aqueous solubility. The majority of their studies thus
focused on CuL2 and CuL3. Co-localization experiments with
immunostained Ab plaques provided evidence that CuL2 and
CuL3 would bind effectively to Ab plaques in post-mortem
human brain tissue (Fig. 4).
Subsequent radiolabelling experiments demonstrated marked
differences between the aqueous soluble 64CuL2 and –L3, in
which 64CuL2 produced only a weak PET signal in the brain
after administration, a finding interpreted in terms of poor brain
uptake. However, with CuL3, the complex incorporating an
appended N,N-dimethylaminoethylene unit, a marked increase
in BBB penetration was inferred. Biodistribution experiments
Scheme 1 Intracellular reduction of Cu2+ (glyoxal-bis(N4-methyl-3-
thiosemicarbazonato)) [Cu(gtsm)], which leads to the release of free
Cu+ ions.
Fig. 2 Non-metal-based PET imaging agents for the visualisation of Ab
plaques in vivo.
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in normal mice showed CuL3 had excellent brain uptake:
1.11% ID g1 at 2 min post injection, and excellent washout
with limited accumulation, 0.38% ID g1 at 30 min. This
work highlights some of the challenges associated with
developing imaging agents that can effectively penetrate
the BBB.
More recently, Mirica and co-workers reported a series
of 64Cu-PET agents (TACNL1 and PPL2–5) for the imaging of
Ab plaques.12 These imaging agents consisted of a 1,4,7-
triazacylononane (TACN) or 2,11-diaza[3.3](2,6)-pyridinophane (PP)
ligands conjugated to 2-phenyl-benzothiazole, which resembles
the well-known Ab-binding dye Thioflavin T (ThT) (Fig. 5). The
corresponding Cu complexes were shown to exhibit low nano-
molar affinity for Ab aggregates in vitro and ex vivo with the
best binding system proving to be with PPL2. Radiolabelling
experiments were then carried out under aqueous conditions
(45 1C, 20 minutes, 0.1 M NH4OAc, pH 7). Radiochemical yields
of greater than 95% were obtained for L1–L5. The resultant
complexes were then used for imaging studies without
additional purification. Biodistribution studies demonstrated
promising brain uptake in wild-type mice followed by rapid
clearance. In vivo PET imaging experiments in AD (Tg2576)
transgenic mice revealed radiotracer accumulation in the neck
and head for 64Cu-PPL2,
64Cu-PPL4, and
64Cu-PPL5. In contrast, no
appreciable brain uptake was seen in the case of 64Cu-TACNL1.
The highest brain uptake and tracer accumulation was seen in
the case of 64Cu-PPL2, a finding that mirrored what was seen in
the in vitro Ab experiments.
Efforts with Cu-based PET agents have provided insight
into the design criteria that need to be addressed to obtain
an effective in vivo imaging agent. In the case of the Donnelly
and Mirica studies summarised above, synthetic modification
of the chelating motif and judicious choice of targeting unit
were crucial in endowing the most effective system with the
appropriate properties, particularly BBB penetration. However,
continued efforts will be required to evaluate further the
potential of these promising candidates as markers for AD.
We also believe that additional effort focused on creating next
Fig. 3 Cu(atsm) hybrids functionalised with the benzothiazole and dimethylaminostyrenyl targeting Ab ligands highlighted in blue.
Fig. 4 AD human brain sections with 1E8 antibody stained Ab plaques and fluorescence microscopy of CuL2 (left) and CuL3 (right) binding to Ab plaques.
Reproduced with permission from (J. Am. Chem. Soc., 2013, 135, 16120–16132). Copyright (2019) American Chemical Society.
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generation Cu-based PET imaging will allow the scope of utility
to be expanded to include other neurodegenerative diseases
(e.g., Huntington’s, ALS, etc.). That researchers will be able to
capitalize upon the plethora of Cu ligands found within the
bioinorganic and inorganic communities is expected to facilitate
these efforts and codify Cu-based PET as a tool to understand
better and diagnose more effectively CNS neurodegeneration.
Gallium (68Ga) – PET
Gallium-68 (68Ga, t1/2 = 1.13 h)-based PET radiotracers are
becoming attractive as imaging agents owing to the ready
availability of gallium-68 from a 68Ge/68Ga generator and an
ideal half-life, which complements the biodistribution times
typically seen for small molecules. However, widespread adoption
of 68Ga-based PET radiotracers has been slow due to concerns
associated with the high energy positron emission characteristic
of gallium-68 and the resulting high levels of radioactivity
(Table 1). However, these concerns are balanced by the commer-
cial availability of 68Ge/68Ga generators, leading us to predict that
gallium-68 radiotracers will continue to find utility in the clinic.
The most prevalent oxidation state of gallium is the charge
dense Ga3+ ion, which forms complexes of CN 4–6. Typical
Ga3+ complexes are based on the use of hexadentate ligands
containing multiple hard anionic donors, such as 1,4,7,10-tetra-
azacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,4,7-
triazacyclononane-1,4,7-triaceticacid (NOTA), and diethylene-
triaminepentaacetic acid (DTPA) (Fig. 6).5 The metallation
of these ligands often requires relatively harsh conditions
Fig. 5 (top) Structures of Cu chelators (TACNL1 and PPL2-5) that are conjugated to a series of Ab ligands, targeting moieties (highlighted in blue) and
(bottom) in vivo PET imaging experiments in AD (Tg2576) transgenic mice carried out using 64Cu-TACNL1,
64Cu-PPL2,
64Cu-PPL4, and
64Cu-PPL5. The
best uptake was seen for 64Cu-PPL2 with little or no brain uptake being seen in the case of
64Cu-TACNL1. Adapted with permission from (J. Am. Chem.
Soc., 2017, 139, 36, 12550–12558, https://pubs.acs.org/doi/10.1021/jacs.7b05937). Copyright (2019) American Chemical Society.
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(elevated temperatures, prolonged reaction times) to achieve
Ga3+ chelation. Alternative chelators have thus been developed,
allowing for improved radiolabelling conditions.2 In this
section, we highlight select examples using gallium-68 for the
development of PET-based imaging agents that are designed to
target neurodegenerative disease.
Seeking to take advantage of the properties of gallium-68 for
use in PET imaging and drawing inspiration from previous small
molecule Ab aggregate probe structure–activity relationship
studies (Fig. 2), Saji et al. developed a benzofuran–Ga–DOTA
conjugate displaying a high affinity towards Ab aggregates
in vitro and in vivo (Fig. 7).13 Here, the radiolabelled benzo-
furan–Ga–DOTA conjugate was isolated in 26% yield (499%
purity) by heating the ligand and Ga(NO3)3 in an ammonium
acetate buffer (pH 5.8) at 100 1C for 10 min. In vitro binding
assays provided support for the conclusion that appending a
68Ga–DOTA metal complex to the benzofuran targeting moiety
had little effect on the binding affinity towards Ab42 aggregates
(Ki = 10.8 nM). Subsequent in vitro staining of brain tissue
revealed effective binding to Ab plaques in a tissue section
derived from an AD mouse model (Tg2576). Unfortunately,
biodistribution experiments in a normal mouse displayed low
initial uptake (0.45% ID g1) in the brain at 2 min post-injection.
Currently, it is an open question as to whether additional
synthetic modifications will allow for brain uptake. Nevertheless,
these results serve to illustrate a simple strategy for developing
68Ga complexes that bind to Ab aggregates in vitro.
Mishra and co-workers reported a 68Ga chelator-targeting
system obtained by conjugating the Ab binding dimethylamino
chalcone motif to DTPA (Fig. 8).14 In this case, rapid
68Ga3+ insertion was achieved in acidic sodium acetate buffer
within 10 min (65–70 1C, pH 4.5–5.0). In vitro binding assays
demonstrated a high binding affinity towards Ab aggregates
(Ki = 4.18 nM), as monitored by the formation of the fluorescent
chalcone-bound Ab aggregates. In particular, upon presumed
binding, a blue shift and a 5.5-fold increase in fluorescence
emission intensity ascribed to the Ga–DTPAchalcone complex was
observed. This study demonstrated the advantages of a dual-
modal PET and fluorescence imaging system as a more refined
technique in disease imaging. Animal studies and biodistribu-
tion analysis of Ga–DTPAchalcone revealed BBB penetration with
brain uptake of 1.24% ID g1 at 2 minutes post injection and
rapid washout with negligible activity (0.36% ID g1) after
30 minutes. No further biological experiments were performed.
Thus, it is difficult at present to assess fully the potential of this
PET imaging agent. However, the work as reported does serve to
underscore a potentially exciting new approach to developing
PET imaging probes for AD.
Asti and co-workers reported a 68Ga-labeled curcumin
complex for the imaging of Ab plaques (Fig. 9). Curcumin
is a phytocompound commonly used in traditional Eastern
medicines to which salutary antioxidant, anti-inflammatory,
antimicrobial, and anticancer activities have been ascribed.15
The relative planarity of curcumin endows this natural product
with an inherent affinity towards Ab plaques. In the Asti study,
curcumin and two synthesised curcumin derivatives, diacetyl-
curcumin (DAC) and bis(dihydroxy)curcumin (bDHC), were
used to form 2 : 1 complexes with 68Ga3+ in good-to-excellent
yields with a short reaction time when heated at 100 1C in a
sodium acetate buffer (pH 5). In vitro studies revealed moderate
to high affinities for Ab plaques. The inherent fluorescence
properties of these complexes allowed their cellular uptake to
Fig. 6 Chemical structures of ligands commonly used to prepare
complexes of Ga3+.
Fig. 7 Benzofuran–Ga–DOTA conjugate reported by Saji and co-workers.
The benzofuran Ab targeting ligand is highlighted in blue.
Fig. 8 A multi-component complex, Ga–DTPAchalcone, reported by
Mishra and co-workers. The chalcone Ab targeting ligand is highlighted
in blue.
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be monitored readily in the A549 human lung cancer cell line.
No further biological experiments were carried out; however,
this research underscores the potential that 68Ga-curcumin-
based systems may hold as potential diagnostic tools in the
area of neurodegenerative disease imaging.
Zirconium (89Zr) – PET
Zirconium-89 (89Zr) has become one of the most popular PET
radioisotopes for use with biological targeting/therapeutic
agents due to its long half-life (t1/2 = 78.4 h). This has enabled
the use of 89Zr monoclonal antibodies (mAb) conjugates
(typical biological half-lives = 7 days) for the development of
‘‘immuno-PET’’ radiotracers.16 The use of immuno-PET radio-
tracers has allowed for more precise targeting of disease-related
biomarkers, such as specific neurotoxic protein aggregate con-
formations. This specificity is expected to provide new insights
into neurodegenerative disease and guide the development of
treatment protocols that could be individualised from patient
to patient.5
The high charge and small radius of Zr4+ (CN 4–9) forces a
preference toward polyanionic hard donor chelators, such
as ethylenediaminetetraacetic acid (EDTA) and diethylenetri-
aminepentaacetic acid (DTPA). However, the well-known iron
(Fe) chelator desferrioxamine B (DFO) has also found utility in
in vivo zirconium-89 PET-based applications (Fig. 10).
Fissers et al. have recently reported studies detailing the
development of a 89Zr immuno-PET strategy for the targeted
imaging of Ab plaques in AD (Fig. 11).17 This work relies on
the use of the bifunctional chelator p-isothiocyanatobenzyl
desferrioxamine (Df-Bz-NCS), a system routinely used for the
rapid and efficient preparation of Zr-89-labeled mAbs. Taking
advantage of the isothiocyanate moiety, Df-Bz-NCS was coupled
to the amino residue of the antibody JRF/AbN/25, an N-terminal
end-specific mAb targeting the full-length human Ab epitope.
Complexation of the resulting construct, Df-Bz-JRF/AbN/25,
with 89Zr was successfully achieved under aqueous conditions
(HEPES buffer) at room temperature to afford [89Zr]Df-Bz-JRF/
AbN/25 in an average yield of 48.39  12.33%. An in vitro
binding assay provided evidence of a high binding affinity
towards Ab40 (Kd = 0.85 nM) with no non-specific binding being
observed. This high binding affinity was further validated by
in vitro autoradiography studies on brain sections from AD
Tg mice models. No obvious binding was observed in brain
sections of normal mice. [89Zr]Df-Bz-JRF/AbN/25 demonstrated
good in vivo stability (i.e., up to 48 hours post injection).
[89Zr]Df-Bz-JRF/AbN/25 demonstrated the ability to penetrate
the BBB resulting in modest brain uptake in normal mice, thus
showing promise as an 89Zr immuno-PET strategy. Unfortunately,
no further biological experiments were carried out. Moreover,
in vitro studies revealed instability in plasma.
Further studies within the context of developing Zr-based
imaging systems should focus on functionalising the best
extant systems to improve brain uptake, as well as the synthesis
and study of new Zr chelators with improved physicochemical
properties. Different mice models should also be screened
to allow the utility of these systems across a range of neurode-
generative disease indications.
Technetium (99mTc) – SPECT
The invention of 99mTc/99Mo generators revolutionised nuclear
medicine, facilitating the production of the technitium-99m
radioisotope and lead to its daily availability in major hospitals.
Not surprisingly, this led to a surge in the development of
99mTc-based radiotracers and use of 99mTc as a popular choice
for the imaging of a range of diseases. One of the key attributes
of 99mTc-based radiotracers, which has led to the predominance
of this isotope in the field of nuclear medicine, is the ability to
synthesise a range of technitium-99m complexes via a one-pot,
one-step ‘‘kit’’ process. This simplicity meant that many sterile
99mTc-based radiotracers could be produced daily with minimal
technologist input or without costly equipment.
Fig. 10 Chemical structures of commonly used 89Zr chelators, ethylene-
diaminetetraacetic acid (EDTA) and desferrioxamine B (Df).
Fig. 9 Ga-curcumin complex for the imaging of Ab plaques reported
by Asti and co-workers. The curcumin Ab targeting ligand is highlighted
in blue.
Fig. 11 DFO-based 89Zr immuno-PET imaging agent developed by Fis-
sers et al. with the goal of achieving enhanced Ab plaque imaging. The
monoclonal antibody (mAb) Ab plaque targeting unit is highlighted in blue.
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None of the isotopes of Tc are stable enough for routine
bench chemistry. However, the similar ionic radius of rhenium
(Re) to that of Tc has led to its use as a cold-laboratory (non-
radioactive) surrogate for Tc-based complexes. On this basis,
various core Tc ion complexes, such as: 99mTc(V)O3+,
CpTc(IV)(CO)3
3+, Tc(IV)N2+, Tc(III)(CO)3
3+, and Tc(I)(CNR)6
+, have
been characterised to date.5 One of the most commonly used
ligands is the N2S2 donor, bis-aminoethanethiol (BAT); it forms a
complex with 99mTc(VI)O3+ that is stable in vivo. For more in-
depth information on the history and various biological targets
of 99mTc SPECT imaging agents, the reader is directed to the
excellent review by Blower.2 Analogous to the metal complex-
targeting conjugate systems used in PET, motifs capable of
detecting specific biomarkers in neurodegeneration have been
developed utilising [99mTc]-SPECT conjugates. In this section,
we highlight selected examples of technetium-99m-based sys-
tems being explored as SPECT imaging agents for neurodegen-
erative disease.
An important application of SPECT-based imaging agents
has been towards understanding the role of the dopamine
transporter (DAT) in a number of neurological processes.
Catecholamine neurotransmitters are crucial for maintaining
homeostasis throughout the autonomic nervous system. Altered
DAT activity has been shown in a number of neurological
disorders, with a reduction in DAT being observed in post-
mortem examinations of patients with PD and AD. Patients with
PD have also been shown to have a selective loss of dopamine
neurons in the basal ganglia and substantia nigra.18
DAT antagonists that display a high binding affinity, such as
cocaine, are generally constructed around a tropane scaffold
(Fig. 12). Influential efforts by Kung and co-workers utilized
the tropane motif to design [99mTc]TRODAT-1, a BAT-tropane
conjugate (Fig. 12). [99mTc]TRODAT-1 demonstrated nanomolar
binding affinity towards DAT in rat striatal homogenate
(Ki = 8.7 nM). Ex vivo autoradiography results further confirmed
high uptake and retention in the striatal region. These promising
results led to the study of [99mTc]TRODAT-1 in normal healthy
human subjects. The radiotracer was found to localize in the
basal ganglia, a finding consistent with selective DAT binding.
Dosimetry studies confirmed that [99mTc]TRODAT-1 was safe for
administration to humans and that it could be used in imaging
DAT for the diagnosis of PD.19 However, [99mTc]TRODAT-1 has
now been largely supplanted by the alternative iodine-123 imaging
agent, [123I]FP-b-CIT (DaTSCAN), due to a world-wide shortage
of the parent isotope, 99Mo, needed to produce 99mTc.4
In continuation of their efforts involving the use of labelled
benzofuran compounds for Ab detection, Saji and co-workers
reported three [99mTc]-pyridyl benzofuran complexes (Fig. 13).20
The 99mTc and corresponding Re complexes were synthesized
using BAT as the chelating ligand. In vitro assays provided
evidence of strong affinity towards Ab42 aggregates (Ki = 13.6–
149.6 nM) for the Re complexes. Biodistribution analyses of
[99mTc]BAT-Bp-2 in normal mice (ddy mice) revealed brain
uptake post injection, 1.80% ID g1 at 2 minutes, with moderate
Fig. 12 Chemical structure of cocaine, a well-known DAT antagonist, and
TRODAT-1, developed as a potential DAT SPECT imaging agent. The
tropane core targeting unit is highlighted in blue.
Fig. 13 The [99mTc]-pyridyl benzofuran complexes ([99mTc]BAT-Bp-n, where n = 1–3) developed by Saji and co-workers. The 2-pyridylbenzofuran- Ab
targeting ligands are highlighted in blue. Ex vivo autoradiography with [99mTc]BAT-Bp-2 illustrating labelling of Ab plaques in sections of brain tissue
from an AD transgenic (Tg2576) mouse versus age-matched controls (wild-type). Reprinted (adapted) with permission from (J. Med. Chem., 2012, 55,
2279–2286). Copyright (2019) American Chemical Society.
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washout, 0.79% ID g1 in the brain at 60 minutes, that was
deemed sufficient to encourage further study. Furthermore, ex vivo
autoradiography with [99mTc]BAT-Bp-2 revealed substantial labelling
of Ab plaques in sections of brain tissue from an AD transgenic
(Tg2576) mouse versus age-matched controls (Fig. 13).
Zhang and co-workers later reported a structural variant of
the BAT conjugate containing a 2-arylbenzothiazole moiety.21
A competitive binding assay identified seven Re complexes with
potent binding affinity toward Ab42 aggregates (Ki o 50 nM).
Radiolabelling with 99mTc yielded no significant differences in
the binding of the [99mTc]BAT conjugate probes with Ab42
plaques. [99mTc]BAT-benzothiazole conjugate 1 displayed ideal
pharmacokinetics with a brain uptake of 2.11% ID g1 at 2 min
and good washout of 0.62% ID g1 at 60 min in normal mice.
Subsequent ex vivo autoradiography experiments revealed
extensive labelling of Ab plaques in brain tissue from AD Tg
mice versus age-matched healthy controls. SPECT imaging
studies in non-human primates (rhesus monkeys) were also
performed. The semiquantitative data resulting from these
studies provided support for the notion that [99mTc]BAT-
benzothiazole (1) penetrates the BBB of healthy rhesus
monkeys (Fig. 14).
Despite metal-based SPECT imaging agents having several
advantages, [99mTc]TRODAT-1 is among a select few agents that
have actually been used for the clinical diagnosis of neurode-
generative disease. However, as summarised above, a number
of promising agents have been reported that underscore how
[99mTc]-based systems may have an increased future role in
creating improved SPECT imaging agents for CNS disorders.
However, balanced against promise are the current supply
problems associated with the required parent isotope, 99Mo.
Indium (In) – SPECT
Indium-111 is an isotope characterized by a long half-life (t1/2 =
67.3 h, g-rays emission – 245 keV). It is thus attractive for
conjugation to targeting biomolecules with slow pharmacoki-
netics, such as mAb. Indium-111 has been the radioisotope of
choice for this purpose since the 1980s and was the first
radioisotope to be commercially and clinically approved for
bioconjugation. Similar to Ga3+, the predominant oxidation
state of indium under most aqueous conditions is In3+. Poly-
anionic, hard donor chelators, such as EDTA, DTPA, and DOTA,
have been the ligands of choice for forming In-complexes with
good aqueous stability (Fig. 6 and 10).
The use of 111In-based SPECT to study neurodegenerative
disease has focused on attempts to address issues with
BBB penetration and lack of in vivo binding seen with other
small-molecule and mAb conjugate systems. For instance,
Pardridge et al. reported an Ab-peptide based radiotracer,
which was designed to deposit 111In at pre-existing Ab plaques.
The Pardridge system was constructed by conjugating biotin at
the N-terminus of Ab peptide and attaching DTPA chelator
subunits to key lysine residues (Lys16 or Lys28) (Fig. 15).22
Ex vivo autoradiography studies provided support for the
expectation that significant binding to Ab plaques from brain
sections of patients with AD could be achieved. However, additional
quantitative binding studies and in vivo kinetic analysis were not
reported. Despite indium-111 being well established in the field
of immuno-based imaging, the rise of 89Zr as a more readily
available and longer-lived surrogate is seeing 111In-based SPECT
agents being increasingly replaced by their 89Zr-based immuno-
PET counterparts.
Magnetic resonance imaging (MRI) in
neurodegenerative disease
Optimization of imaging instruments and the availability of a
number of small molecule probes, known as contrast agents (CAs)
Fig. 14 Chemical structure of [99mTc]BAT-benzothiazole conjugate 1
reported by Zhang and co-workers with the benzofuran targeting moiety
highlighted in blue. SPECT images of [99mTc]1 in rhesus monkeys
(A: 4 years old, male; B: 27 years old, female); SPECT images are overlaid
on individual co-registered CT images. Reprinted (adapted) with permis-
sion from (Bioconjugate Chem., 2016, 10, 2493–2504). Copyright (2019)
American Chemical Society.
Fig. 15 Ab-peptide based 111In radiotracer developed by Pardridge et al.
The biotin targeting unit is highlighted in blue.
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has made magnetic resonance imaging (MRI) a powerful
technique within the imaging paradigm. In comparison to
PET and SPECT, MRI is generally cheaper, more widely acces-
sible, and provides higher spatial and temporal resolution
(40.01–1 mm and 40.01–1 s) with enhanced (total) depth
penetration through biological tissue. These properties make
MRI an excellent tool for in vivo studies and clinical use. A major
advantage of MRI over radiotracer (PET/SPECT) approaches is
that MRI CA signals can be modulated by environmental
changes or via exposure to specific analytes, allowing for real-
time functional imaging (i.e., fMRI) in living subjects. However,
as a general rule MRI lacks the sensitivity seen for PET and
SPECT. Recent efforts within the MR imaging community have
focused on the development of tools that enable the imaging
of neurodegenerative diseases.23 For extensive coverage of the
theory and development of MRI contrast agents, current direc-
tions, and challenges for the field, the reader is directed to two
excellent reviews by Meade23 and Caravan.24
The most common contrast agents for MRI utilize a poly-
dentate ligand with a coordinated paramagnetic metal ion
(e.g., Gd3+, Fe2+/3+, and Mn2+/3+). The operational mechanism
for MRI involves administration of the contrast agent followed
by the application of a short radiofrequency (RF) pulse to a
sample (e.g., human, mouse, or test-tube) placed within an
external magnetic field (i.e., the scanner). This RF pulse results
in the excitation of the nuclear spins of surrounding water
protons, which then relax to the equilibrium of the external
field. The rates of the relaxation, based upon the longitudinal
(T1) and transverse (T2) time constants, are dependent upon the
specific environment of the water molecules. It is the variation
of these rates that forms the basis of the signal intensity in
typical anatomical and contrast-enhanced MRI.
Paramagnetic metal ions, such as Gd3+, Fe2+/3+, and Mn2+/3+,
contain unpaired electrons. These ions generate magnetic moments
that interact with nearby water molecules to increase proton nuclear
relaxation rates. The extent to which a contrast agent can change
the T1 or T2 of water is generally defined by relaxivity, r1 or r2,
respectively. Relaxivity is the change in bulk relaxation rate per unit
of contrast agent, normally in units of mM1 s1, and is defined by
eqn (1). Briefly, (1/T0i ) is the relaxation rate in the absence of the
contrast agent, (1/Ti) is the relaxation rate in the presence of contrast
agent, and [CA] is the concentration of the MRI contrast agent.
1
Ti
¼ 1
T0i
þ ri½CA; i ¼ 1; 2 (1)
As a general rule, the greater the relaxivity (ri) of a contrast
agent, the better the CA increases the rate of relaxation of
nearby protons. This enhancement generally manifests as
an improved resolution contrast image. Additional changes to
the contrast image can also occur depending upon the local
environment. Indeed, the relaxation times of endogenous water
molecules vary upon interacting with macromolecules (e.g.,
proteins and DNA) generating a contrast difference in T1- and
T2-weighted images compared to standard conditions.
Due to the physical processes underlying relaxation rates,
T2 is always shorter than T1. The T2 is thus more difficult to
modulate via the addition of contrast agents. In the case of
standard Gd3+ contrast agents with relatively similar r1 and r2
values, the slower T1 will display a larger percent modulation
than the faster T2. Traditionally, small molecule CAs have been
used to increase the signal change in the T1-weighted image
(Fig. 16a). For transverse relaxation of these small molecule
probes, the observed T2 or T2* is shorter than the true T2 due to
field inhomogeneities and other factors. Efforts to generate
meaningful changes in T2 have focused on the use of nano-
particle systems. The resulting systems are referred to as T2, or
T2* MRI contrast agents; they generally lead to a decrease in the
signal of T2/T2*-weighted images.
For T1-weighted contrast agents, three main factors deter-
mine the relaxivity of the agent:
 q – average number of water molecules bound directly to
the paramagnetic metal centre.
 tm – mean residence lifetime of the bound water molecule,
i.e., the inverse of the water exchange rate (kex).
 tr – rotational correlation time, i.e., how rapidly the mole-
cule tumbles (rotates) in solution.
In the case of parameter q, water molecules in the first
coordination sphere of the metal complex experience the great-
est T1 enhancement. Thus, the larger the q-value the higher the
r1 value (Fig. 16b). For tm, an exchange rate optimised to the
timescale of relaxation will generate the highest relaxation
enhancement. To date, tm remains difficult to predict, measure,
and implement in CA design (Fig. 16c). However, manipulation of
tr is a commonly employed strategy and achieved by increasing
the molecular weight of the MRI contrast agent (e.g., by binding to
a protein, as larger molecules tend to tumble and rotate much
slower) (Fig. 16d). For T1 contrast agents, changes in tr have
minimal effects at higher field strengths (43 T), limiting use of
such systems in high-field preclinical and ultra-modern clinical
scanners. For T2-weighted agents, changes in tumbling rates are
still an effective way to modulate contrast at any field strength.
Aggregation remains the primary method for functional imaging
with T2-probes. Alternative methods, such as chemical exchange
saturation transfer (CEST) and paramagnetically-enhanced
chemical shift imaging, are available, but due to the limited
applications in neurodegenerative disease imaging they will not
be covered in this review. For further details on applications of
these techniques, we refer the reader to the aforementioned
reviews.23,24
The MRI imaging section will be divided by each para-
magnetic metal ions Gd3+, Fe2+/3+, and Mn2+/3+ with focus on
the precise method and biomarker relevant to neurodegenera-
tive diseases. These examples will demonstrate both targeted
and functional approaches.
Gadolinium (Gd3+) – MRI
Gd3+ has the largest number of unpaired electrons for an
aqueous stable ion (S = 7/2), a high available coordination
number (CN 7–10), and close-to-ideal electronic relaxation rate
that optimises its ability to increase the relaxation rate of water
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protons through simple water–metal interactions.24 However,
free Gd3+ metal ions display off-target toxicity, requiring the use
of a tight binding chelator. Polydentate and hard anionic
donors, such as those found in diethylenetriaminepentaacetic
acid (DTPA) and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra-
acetic acid (DOTA), remain the ligands-of-choice for Gd-based
MRI contrast agents in academic research and clinical use. Due
to its higher thermal stability and worries of systemic toxicity
resulting from leaching of Gd3+ from linear chelators (e.g.,
DTPA), the macrocyclic DOTA is now preferred for new applica-
tions, as illustrated throughout this MRI section.23
MRI-based imaging of CNS disorders has focused on
methods of targeted (MRI) or functional imaging (fMRI).
Recent efforts towards targeted imaging have utilized metal
complex-targeting conjugates analogous to PET/SPECT. An
exemplary demonstration of such efforts was recently reported
by DeBeof and co-workers using arecoline- and tropane-based
Gd–DOTA metal complexes for the selective MRI imaging of
DAT.25 DeBeof and associates recognized that small molecule
binding within a macromolecular biomarker would yield
an enhancement in T1 via modulation of the molecular
rotation (tr). The tropane-derived CA-1 (Fig. 17) produced a 38%
increase in the r1 value from 6.32 mM
1 s1 to 8.71 mM1 s1 in
the presence of DAT-transfected HEK293 cells at a 7 T magnetic
field. Binding studies with tropane-derived CA-2 revealed a high
binding affinity to DAT, similar to that of the DAT antagonist
cocaine (303 nM). Unfortunately, due to the relative insensitivity
of MRI, which typically requires410 mMdetectable concentration
of contrast agent, and DAT only being present at nM concentra-
tions in vivo, these probes were not pursued further in the context
of potential biological applications. However, this work provided
an elegant demonstration of combining targeted molecules with
manipulation of tr towards the detection of neurodegenerative
biomarkers.
Fig. 16 (A) Simplified illustration showing the two main ways in which MRI has been applied towards neurodegenerative imaging; targeted imaging by
selective accumulation of contrast agent and functional imaging, where the signal is modulated by presence of an analyte. (B–D) Illustration of
the common methods for developing functional T1 contrast agents: (B) modulation of bound water, q; (C) optimisation of water exchange rate, tm;
(D) binding to a higher molecular weight conjugate to alter rotational correlation time, tr.
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A similar Gd–DOTA-targeting moiety conjugate strategy was
recently used by Wang and co-workers to effect the MR imaging
of myelin.26 Myelination is a fundamental biological process
within the nervous system, which involves the formation of
myelin sheaths along neuronal axons for rapid and efficient
conduction of nerve impulses. Abnormalities or destruction
of myelin results in the neurodegenerative disorder Multiple
Sclerosis (MS). The ability to visualise and discriminate between
healthy and abnormal myelin in vivo could provide insight into
this disease and mechanisms behind its progression.
In an attempt to visualize myelination with MRI, Wang and
co-workers developed a first-generation conjugate that was
prepared by appending a known myelin selective coumarin-
based fluorescent probe to Gd–DOTA to form the MRI contrast
agent, myelin dye-1 (cf. Fig. 18). Ex vivo imaging of partially
demyelinated mouse and rat brain tissue stained with myelin
dye-1 revealed discrimination between regions that were high
and low in myelin. Subsequent MRI T1 mapping of brain tissue
complemented the fluorescence data, and provided support for
the suggestion that retention of myelin dye-1 is proportional to
the level of myelination in the brain. Due to the polar nature of
myelin dye-1, intra-cerebroventricular infusion was required to
bypass the BBB and enable in vivo imaging of demyelinated
lesions in L-a-lysophosphatidylcholine (LPC) treated rats. MRI
mapping yielded relatively long T1 values in demyelinated
lesions, a result ascribed to little or no binding of myelin dye-
1 in these latter samples. These efforts highlight the potential
of MRI contrast agents that can selectively bind to myelin
in vivo and underscores the promise they may have in terms
of facilitating early diagnoses of MS and monitoring treatments
aimed at myelin repair.
Analogous to the PET and SPECT conjugate literature,
Ferroud and co-workers designed a series of Gd3+-based MRI
conjugated contrast agents comprising of an Ab aggregate
targeting moiety, a linker, and a Gd3+ chelator (Fig. 19).27
Ferroud et al. carried out a structure activity relationship
(SAR) study on 16 different contrast agents, varying the Gd3+
chelator from DOTA to PCTA (3,6,9,15-tetraazabicyclo[9.3.1]-
pentadeca-1(15),11,13-triene-3,6,9-triacetic acid), the Ab target-
ing ligand between 2-arylbenzothiazole, 2-arylbenzoxazole, and
various stilbene derivatives, and the charge of the linker from
neutral to overall positive or negative while likewise adjusting its
length. The resultant complexes showed good water solubility
with nanomolar binding affinities to Ab aggregates. However,
they failed to pass through an intact (healthy) BBB. This short-
coming again highlights the significant challenges associated
with developing effective imaging agents that have both high
affinity for a neurodegenerative biomarker and the ability to
penetrate the BBB.
DOTA-type macrocycles ligate to eight of the nine available
Gd3+ coordination sites, leaving one site available for an inner
sphere water molecule.23 The Meade group has exploited this
free binding site by pioneering the development of q-modulated
MRI contrast agents. Such systems are designed to only allow
inner-sphere access of water upon binding to the target analyte
(biomarker). A seminal contribution by Meade and co-workers
was the development of a calcium ion (Ca2+) responsive MRI
agent, in which the relaxivity was controlled by the reversible
binding of Ca2+ ions.28
Ca2+ ions play a vital role in maintaining proper cell function
with deviations in neuronal Ca2+ signalling being correlated
with a number of neurodegenerative diseases. The Ca2+-responsive
Fig. 17 Chemical structures of tropane and arecoline MRI-analogues, CA-1 and CA-2.
Fig. 18 (left) Chemical structure of myelin dye-1 with the coumarin targeting moiety highlighted in blue and (right) T1 mapping of a Sprague–Dawley rat
brain proximal after 5 h post injection. The dark regions (short T1) are indicative of increased binding in areas of myelination. Reprinted (adapted) with
permission from (J. Med. Chem., 2012, 55, 2279–2286). Copyright (2019) American Chemical Society.
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MRI contrast agent developed by Meade and co-workers incorpo-
rated a seven-coordinate DOTA analogue, 1,4,7-tris-(carboxymethyl)-
1,4,7,10-tetraazacyclododecane (DOPTA), wherein q can vary from 0
to 2 and was linked to the 1,2-bis(o-aminophenoxy)ethane-N,N,N0,N0-
tetraacetic acid (BAPTA) Ca2+ binding subunit via a propyl
chain (Scheme 2). In the absence of Ca2+, the aromatic imino-
acetates of the BAPTA moiety interact with the Gd3+ centre. The
presence of Ca2+ modulated the binding of the aromatic
iminoacetates such that they interacted with the Ca2+ ions,
rather than the Gd3+ centre. The resulting exposure of the Gd3+
centre to water molecules caused a change in relaxivity. Thus a
stimulus-responsive (Gd–DOPTA)2–Ca
2+ sensor was produced
that was found to have high sensitivity toward Ca2+ (detection
range: 0.1 to 10 mM). This MR-based sensor was found to
display a 1 : 1 stoichiometry for the Ca2+ ion triggers and
produce an 80% overall increase in relaxivity upon Ca2+ com-
plexation. This work stands as an excellent initial example of
how to manipulate various parameters (e.g., q) to enact an
effective change in T1 signal. Unfortunately, application of
these agents in the context of neurodegenerative disease has
been limited due to difficulties in tuning the calcium affinity and
MRI sensitivity to match the relative intracellular (0–100 mM) and
extracellular (0.1–2 mM) calcium fluctuations typically seen in
the brain. Applications may also prove limited by an apparent
lack of cell permeability.
Chang and co-workers developed a class of Cu+ responsive
q-modulated MRI contrast agents as potential tools for studying
copper dysregulation in neurodegenerative diseases.29 The gen-
eral scaffold was a Gd–DOTA analogue featuring a thioether-rich
conjugate (Scheme 3). In the absence of Cu+ ions, the nitrogen
on the pyridine ring unit coordinates the Gd3+ centre, restricting
inner sphere water coordination. Upon addition of Cu+, the pyridine
nitrogen and thioether moiety undergoes a conformational change,
a chemical switching event that serves to ‘‘turn off’’ the
Gd–pyridine binding interaction. The increased water access
Fig. 19 Structural optimisation of a Gd–DOTA complex for the imaging of Ab plaques.
Scheme 2 q-Modulating Gd–DOPTA–BAPTA contrast reported by
Meade and coworkers that permits the MR-monitored reversible detection
of Ca2+ ions. Upon binding of Ca2+, water access to the Gd3+ ion is
increased, raising the relaxivity and MRI signal of the contrast agent. The
relationship between relaxivity and Ca2+ concentration is displayed in the
lower plot. Reprinted (adapted) with permission from (J. Am. Chem. Soc.,
1999, 121, 1413–1414). Copyright (2019) American Chemical Society.
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to the Gd3+ centre leads to a marked enhancement in the
relaxivity (r1), with the largest overall change in r1 (360%; from
1.5 to 6.9 mM1 s1) being seen in the case of compound CG2.
In order to improve cellular uptake, Chang and coworkers
included an octa-arginine unit to yield Arg8CG2 (Fig. 20).
29 This
system was applied towards imaging a Menkes disease model
fibroblast cell line and control fibroblasts. Menkes disease is
a disorder characterized by a progressive deterioration of the
nervous system. In comparison to the untagged CG2, the
arginine tagged complex showed a remarkable 9-fold greater
accumulation in both cell lines. The overall relaxivity change of
Arg8CG2 was slightly lower than with CG2, but gave a higher
absolute r1 for both the ‘off’ and ‘on’ states (3.9 to 12.5 mM
1 s1).
However, it should be noted that the buffer system was different
for these two studies. While a higher absolute signal will lower the
detection threshold, a larger relative change between the bound
and unbound conditions should lead to greater sensitivity in
determining analyte binding. Phantom MR images of the two cell
lines revealed a higher contrast when Arg8CG2was present than in
its absence. Treatment of the cells with a copper chelator allowed
monitoring of the depletion of intracellular copper through MRI
monitoring, indicating the potential of such an approach for
in vivo biological MRI studies.
Modification of Gd3+-based contrast agents has also yielded
functional systems for monitoring enzymatic function (e.g., gluta-
mate decarboxylase (GAD) activity). GAD is an essential enzyme
converting L-glutamate (L-Glu), an excitatory neurotransmitter, to
g-aminobutyric acid (GABA), a major inhibitory neurotransmitter.
Abnormal variations in GABA-mediated signalling have been linked
to a number of neuropathological conditions, such as PD, epilepsy,
and various psychiatric disorders. Traditional methods for
GAD identification and quantification are based on post-
mortem examinations. The development of non-invasive agents
that would allow GAD activity to be monitored in vivo would
thus be highly desirable; ultimately, they might make it possible
to correlate precise deviations in activity with specific neuro-
degenerative phenotypes.
Hoehn and co-workers recently reported a q-modulated MRI
contrast agent activated by GAD.30 The system was constructed
from Gd-DO3A conjugated to flexible linkers with pendant
glutamate residues (Fig. 21). GAD-mediated decarboxylation
of the pendant glutamates unveiled the Gd3+ centre allowing
inner sphere water coordination. This increase in the hydration
state of the Gd3+ ion (q = 0 to 2) resulted in enhanced relaxivity
with attendant complexation to endogenous macromolecules via
increased electrostatic interactions. The Gd-DO3A-glutamate
conjugate-1 was used to achieve the in vivo imaging of implanted
GABAergic neurons that were differentiated from embryonic
stem cells. Faster relaxation was observed for the differentiated
neurons relative to undifferentiated cells in vitro and in vivo, a
result considered consistent with GAD-specific activation of the
contrast agent in those neurons.
Manganese (Mn2+ and Mn3+) – MRI
Health concerns regarding the use of Gd-based contrast agents
have become a focal point in MRI research. Researchers are
thus actively searching for non-Gd-based alternatives.24 Man-
ganese (Mn2+/3+) has shown promise as a viable alternative with
relatively low inherent toxicity. Manganese is an essential metal
ion in biological systems. Indeed, various inherent biochemical
mechanisms enable the uptake and cell internalisation of Mn
within the brain.31 Even the simple MnCl2 salt has found use
in the manganese-enhanced MRI (MEMRI) visualisation of
brain architectures, neuronal tracts, and brain activity through
T1 and T2 imaging (Fig. 22). However, the relaxivity of Mn
2+
is low compared to Gd3+. As a result, significant amounts
Scheme 3 Chang’s q-modulating Gd3+-DO3A contrast agent that per-
mits the reversible detection of Cu2+ ions via MRI.
Fig. 20 Chemical structure of Arg8CG2 and phantom images of both Arg8CG2 and CG2 in two different cell lines, revealing an increase in signal
intensity in the presence of copper. Reproduced from (Chem. Sci., 2012, 3, 1829–1834) with permission from The Royal Society of Chemistry.
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of Mn2+ are required to produce an effective MRI signal. This
can become a limitation since the Mn2+ concentrations in
question can produce toxic effects, at least in the case of the
free cations.
In an attempt to address the toxicity of free Mn2+ at high
concentrations, Flesch and co-workers developed a first-
generation dendritic DTPA-based Mn2+ complex. The polymeric
network acted as a time-release vehicle for the progressive
delivery of Mn2+ in the brain (Fig. 23).32 This dendrimeric
Mn2+ complex displayed excellent aqueous solubility (0.1 M)
with minimal in vitro neuronal toxicity. For instance, a 100% rat
survival rate was observed when concentrations as high as
20 mM were given via intraperitoneal (i.p.) administration;
presumably, these favourable findings reflect the slow diffusion
of the released Mn2+ cation in vivo. The obtained in vivo images
in the context of this study were also consistent with what was
seen when MnCl2 was injected intravenously. These efforts
serve to outline what might emerge as an effective strategy to
overcome the unwanted toxicity of free Mn2+ at the concentra-
tions needed to effect the MEMRI-based visualisation of brain
structures.
To explore imaging beyondMEMRI and compete with current
Gd3+-based contrast agents, stable small molecule Mn contrast
agents must be developed.24 Jasanoff and co-workers recently
Fig. 21 q-Modulated MRI contrast agent reported by Hoehn and co-workers. This system proved responsive towards glutamate decarboxylase (GAD), a
finding rationalized in terms of the enzyme serving to cleave the terminal acid group and increase the relaxivity of the contrast agent as the result of an
increase in the metal-bound water number, q.
Fig. 22 Example of manganese-enhanced MRI (MEMRI), showing an increased signal intensity throughout the brain with increasing concentration of
MnCl2. Reprinted (adapted) with permission from (Schizophr. Bull., 2008, 34, 595–604). Copyright (2019) Oxford University Press.
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reported the preparation of three in vivo stable, cell-permeable
phenylenediamido (PDA)-based Mn3+ complexes and showed
that they could be used as T1 MRI contrast agents for selective
cell labelling (Fig. 24).33 These Mn3+ complexes displayed a
higher stability compared to Mn2+ complexes due to favourable
chelation between the hard donor, anionic PDA ligand, and the
high-spin 3d4 Mn3+ cation. The open coordination sphere of the
PDA-based Mn(III) complexes also facilitated exchange with
inner-sphere water molecules. Subsequent studies focused on
modification of the ligand scaffold with a BAPTA Ca2+ chelating
unit. These efforts afforded an effective T1 MRI contrast agent
that allowed for the monitoring of intracellular Ca2+ concentra-
tions (Mn-L3-BAPTA). Facile modification of the BAPTA scaffold
allowed this system to be tuned to produce an analogue,
ManICS1-AM, that displayed good cell permeability. Upon
cellular uptake in HEK293 cells, ManICS1-AM undergoes
esterase-mediated cleavage to reveal the BAPTA and enable
monitoring of intracellular Ca2+ concentrations. In vivo studies
provided support for the design expectation that ManICS1-AM
could be used to monitor changes in Ca2+ concentrations
induced via stimulation with potassium ions (K+). This latter
stimulation induces neuronal cell depolarization and gives rise
to changes in the Ca2+ concentrations in brain tissue. ManICS1-
AM apparently constitutes the first example wherein calcium
fluctuations in a living rat brain could be monitored directly at
the intracellular level via fMRI.
Fig. 23 A dendritic DTPA-based complex reported by Flesch and
coworkers that was designed to improved delivery of Mn2+ while decreasing
toxic side effects.
Fig. 24 Phenylenediamido (PDA)-based Mn3+ complexes reported by Jasanoff and co-workers. These complexes act as T1 MRI contrast agents and
permit the imaging of intracellular and in vivo Ca2+ concentrations. (A) When the cell permeable AM-ester protected complex (ManICS1) is internalised in
cells, esterases cleave the AM-ester groups to release the active complex, which is cell permeable and trapped. Binding of Ca2+ causes an increase in
signal intensity due to increased water access to the Mn3+ centre. Early iterations of cell permeable Mn3+ complexes are shown in the inset. (B) The
relaxivity response of ManICS1 to increasing Ca2+ concentration, in comparison to the similar divalent cation, Mg2+. (C) In vivo signal change in a rat
model upon stimulation with potassium, which results in increased neural activity and a spike in intracellular calcium levels. A calcium-insensitive
analogue (MnL1F) give rise to no detectable response under otherwise identical experimental conditions. Reproduced from (Nat. Commun., 2019, 10,
DOI: 10.1038/s41467-019-08558-7) – Open Access.
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Iron (Fe2+/3+) – MRI
Iron, able to form in vivo stable metal complexes in both its
divalent and trivalent oxidation states, is also being explored
actively as a relaxation agent for use in MRI.24 In fact, one of the
most widespread uses of Fe in MRI involves the use of endo-
genous haemoglobin (Hb). The difference between para-
magnetic deoxygenated Hb and diamagnetic oxygenated Hb
can be observed in T2*-weighted images and permits a func-
tional readout through blood oxygenation level-dependent
(BOLD) fMRI (Fig. 25). This method provides real-time informa-
tion on blood oxygenation, blood flow, and blood volume
changes. Data gathered through BOLD fMRI can be used to
obtain indirect insights into the underlying neural activity, as
activation of neurons requires an increased usage of oxygen
and blood flow to the firing cells. This technique has shown
promise as a biomarker for Alzheimer’s disease and other
neurodegenerative disorders.34 However, BOLD fMRI remains
limited by the indirect coupling between neural activity and
vascular response.
Currently, synthetic iron-based contrast agents are being
explored as an alternative to BOLD. In an attempt to gain direct
information on neuronal activity, Jasanoff and co-workers recently
reported an Fe3+-based MRI strategy that relies on a directed
evolution approach utilising bacterial cytochrome P450-BM3
to afford a series of protein-based MRI contrast agents that
permitted dopamine imaging. Dopamine is a monoamine
neurotransmitter vital for proper neurological function.35
Therefore, real time imaging of dopamine activity in vivo is
particularly desirable as malfunction of the dopaminergic
system has been associated with several neurodegenerative
diseases. Dopamine is a substrate (endogenous ligand) for
the bacterial cytochrome P450-BM3. However, in the absence
of this substrate, a water molecule can fill the remaining
coordination site of the Fe3+ atom. Subsequent binding
of dopamine results in an attenuated MRI signal (0.83 
0.01 mM1 s1 - 0.10  0.00 mM1 s1). This change in
signal could be used to achieve the spatiotemporal imaging of
dopamine release from PC12 cells and in the ventral striatum
of brains in live rats following reward-related lateral hypo-
thalamic brain stimulation.35 This seminal work by Jasanoff
and co-workers established a new paradigm in fMRI and
demonstrated directly how it could be applied to the problem
of mapping neuronal function.
For MRI contrast applications, iron is commonly used in the
form of T2 superparamagnetic iron oxide nanoparticles (SPIONs).
Wisniewski and co-workers employed bis-functionalised ultra-
small SPIO (USPIO) nanoparticles with sufficient BBB permeability
for the targeted imaging of Ab plaques.36 These USPIO nano-
particles were constructed via conjugation to the Ab42 peptide
through a polyethylene glycol (PEG) linker. In vivo and ex vivo
imaging of the resulting USPIO-PEG-Ab42 nanoparticles revealed
an ability to image Ab plaques in vivo by means of T2*-weighted
MRI on the mm scale. These imaging-based conclusions were
supported by histological analyses (Fig. 26).
Jasanoff and co-workers have recently reported an elegant
SPION-based imaging strategy for the detection of extracellular
Ca2+ fluctuations that exploits the Ca2+ dependent interactions
between the calcium-binding protein moiety C2AB and a lipid-
coated iron oxide nanoparticle (LCIO).37 In the presence of Ca2+,
the magnetic calcium-responsive nanoparticles (MaCaReNa)
undergo clustering which serves to enhance the protein–LCIO
Fig. 25 The chemistry underlying blood oxygenation level-dependent (BOLD) functional MRI (fMRI). Oxygenation of haemoglobin causes an decrease
in paramagnetism. Neural activity leads to changes in blood flow/oxygenation levels in nearby vessels, which leads to signal changes in MRI.
Fig. 26 Ex vivo mMRI, at the level of the area cinguli of the cerebral cortex,
of a 14 month-old APP/PS1 Tg injected with USPIO-PEG-Ab1–42, showing
numerous dark spots indicating location of Ab plaques. Reproduced from
(PLoS One, 2013, 8, DOI: 10.1371/journal.pone.0057097) – Open Access.
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interactions. Structural changes occur (i.e., aggregation)
that lead to an increase in the hydrodynamic diameter from
35  1 nm in the low calcium regime to 262  14 nm in the
presence of high calcium concentrations. An almost 2-fold
change in r2 accompanies these changes in the Ca
2+ concentra-
tions and considered most relevant to extracellular studies
(i.e., 0.1 to 1 mM). The possibility of studying brain activation
in response to chemical (K+) and electrical stimuli in vivo was
then explored using rats. Observed MRI response times were on
the order of seconds. This work by Jasanoff and co-workers is
arguably the first example of molecular fMRI using an MRI
calcium sensor in a living brain model.
Luminescence-based imaging agents
for the detection of neurodegenerative
disease related biomarkers
Advances in the chemistry of luminescent small molecules and
coordination complexes have provided systems that may be
used for luminescence-based imaging, either alone or in con-
junction with PET, SPECT, or MRI techniques. Luminescence is
defined as the emission of light from a substance (lumino-
phore) in its electronically excited state. Upon exciting the
luminescent optical imaging agent, the corresponding emis-
sion signal can be used to ascertain the location and concen-
tration of the luminophore within a specific biological sample.
The resultant emission can be characterised by its wavelength,
intensity, and the type of emission – Fig. 26A (i.e., length of the
luminescence lifetime; fluorescence o 10 ns versus phosphor-
escenceB ms to ms). A number of optical imaging agents have
been designed that may be used to selectively detect an analyte
of interest, either through a binding event or by means of a
chemical reaction. In comparison to MRI and PET/SPECT,
these luminescent optical agents display unrivalled sensitivity,
specificity, and temporal and spatial resolution. Optical imaging
agents have thus begun to find use in the direct quantification of
specific biomarkers involved in physiological or pathological
processes in real time at the cellular and subcellular levels.
However, due to the limited depth of light penetration through
tissue, luminescence-based imaging is currently restricted to
small live animals for research purposes only.
To achieve optical-based bioimaging, researchers have uti-
lised luminescent imaging agents in the form of organic
compounds, transition metal complexes, lanthanide chelates,
quantum dots, nanoparticles, and fluorescent proteins.38 In the
context of reviewing efforts to image and understand better
CNS neurodegeneration, it is convenient to divide the general
class of metal-based luminescent imaging agents into those
based on transition metal complexes and those that rely on
lanthanide cations.
Transition metal-based imaging agents
The photophysical properties of transition metal coordination
complexes with luminescent properties have been extensively
detailed within the inorganic and material science literature.
These complexes often display large Stokes shifts, high photo-
chemical stability, and tuneable chromatic properties achievable
via ligand modification. Transition-metal complexes applied to
luminescence-based imaging include: Re+, Ru2+, Os2+, Ir3+, Rh3+,
Pt2+, Au+, and Cu+. These systems all exhibit spin-forbidden
triplet-state phosphorescence involving electronic transitions
from the metal ion and ligand (i.e., metal-to-ligand charge-
transfer (MLCT) and ligand-to-metal charge-transfer (LMCT)).
Intra-ligand (IL) and ligand-to-ligand charge-transfer (LLCT) can
also occur and are the result of intra- and inter-ligand transitions,
respectively. Many complexes are subject to metal–metal interac-
tions or ligand–ligand stacking that favour triplet-state phosphor-
escence, dominated by metal–metal-to-ligand charge-transfer
(MMLCT), ligand-to-metal–metal charge-transfer (LMMCT), and
metal-to-ligand-ligand charge-transfer (MLLCT). As a result of the
spin-forbidden nature of the associated relaxation from the triplet
back to the ground state long-lived luminescence emission life-
times are observed for many of these complexes. Researchers have
developed various photoluminescence time-resolved techniques,
such as time-gated luminescence and photoluminescence lifetime
imaging microscopy (TGL and PLIM), that permit discrimination
relative to other interfering fluorescent signals with similar wave-
lengths (Fig. 27).38 This represents a significant advantage for
Fig. 27 (A) Simplified Jablonksi diagram illustrating the difference between fluorescence and phosphorescence, with representative emission lifetimes.
(B) Illustration of the principle behind time-gated imaging and spectroscopy. By applying a time-gate, the excitation pulse (blue) and shorter-lived
fluorescence (green) can be removed from the signal to allow selective detection of long-lived phosphorescence (red).
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metal-based luminescent species compared to, for instance,
traditional organic fluorophores. On the other hand, as a result
of the numerous electronic transitions involving both the metal
and the ligand, the excited states of transition metal complexes
are often sensitive to changes in the surrounding environment
and the nature of the coordinating ligand. These combined set
of attributes makes transition metal-based luminescence-based
imaging agents attractive for the selective detection of analytes,
both in vitro and in vivo.
For an extensive coverage of time-resolved photolumines-
cence techniques and the development of transition-metal
complexes for bioimaging applications, the reader is directed
to two significant reviews by Huang and Li.38,39 In this section,
we present selected examples of transition metal-based lumi-
nescent imaging agents (Ir3+, Ru2+, and Re+) that have been
used to detect biomarkers implicated in the development of
neurodegenerative disease.
Iridium (Ir3+)
Octahedral cyclometallated iridium (Ir3+) complexes remain a
current gold-standard in the area of luminescence. They are
typically characterized by high photoluminescence efficiencies,
good aqueous stability, and excellent colour tunability through
synthetic modification of the coordinating ligand. To date, a
large number of cyclometallated Ir3+-based complexes have
been developed for the imaging of disease-specific biomarkers
in vitro and in vivo.38
As underscored by the imaging agent development efforts
summarised in the earlier portions of this review, the so-called
amyloid hypothesis, focused on the role of Ab plaques in AD
progression, remains a focal point in AD research. Within this
overall paradigm, researchers have set out recently to develop
dual modal tools, so-called theranostics, that are able to
detect Ab peptide and inhibit Ab plaque formation. Ma and
co-workers recently reported a series of Ir3+ and Rh3+ metal
complexes capable of inhibiting amyloid fibrillogenesis
while permitting the attendant luminescence detection of Ab
fibrils.40 These metal complexes are comprised of two cyclo-
metallated (2-phenyl pyridine, C^N) ligands with two bound
solvent molecules (i.e., H2O) (Fig. 28). The labile solvent mole-
cules allow for coordination to the histidine residues (H6, H13,
or H14) present within the Ab fibril framework. A brief structure
activity relationship analysis led to the conclusion that Ir3+ and
Rh3+ metal complexes bearing C^N phenyl-pyridine (ppy)
ligands (i.e., 2a and 2b) provided the greatest inhibition of Ab
aggregation.
In comparison to 2a, the Rh3+-complex 2b was found to be
more active with near complete inhibition of Ab peptide
aggregation at 5 mM, demonstrating its potential as an Ab
peptide inhibitor for the treatment of AD. Unfortunately, 2b
proved weakly emissive. On the other hand, the Ir3+-complexes
2a, 3, and 4 displayed luminescence turn-on in the presence of
Ab peptide. This enabled the use of these latter complexes as
tools to distinguish between the different states of aggregation,
with a higher luminescence emission being observed for Ab
fibril versus Ab monomers.
In follow up work, Ma and co-workers showed that appro-
priately designed Ir3+ complexes could function as dual Ab
fibrillogenesis inhibitors and luminescent imaging agents.41
Toward this end, Ma et al. prepared twelve different lumines-
cent Ir3+ complexes and evaluated their ability to bind to the Ab
peptide. It was found that complex 5, comprised of a 2-phenyl-
1H-imidazo[4,5-f][1,10]phenanthroline (phenyl-imidazo-phen)
(N^N) ligand, was effective in distinguishing between Ab fibrils
over Ab monomers. Continued optimization yielded complexes
6 and 7, with 6 demonstrating partial inhibition and 7 demon-
strating complete inhibition of Ab fibrillogenesis (Fig. 29).
Complex 6 provided for a 6- and 12-fold enhancement in
luminescence emission intensity when contacted with Ab
monomers and fibrils, respectively. Complex 7 proved even
more effective, providing an 11- and 18-fold luminescence
emission enhancement upon treatment with Ab monomers
Fig. 28 Octahedral cyclometallated iridium (Ir3+) complexes developed by Ma and co-workers for the simultaneous detection of Ab peptide and
inhibition of Ab plaque formation.
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and fibrils, respectively. In vitro analysis of complex 7 revealed
a neuroprotective effect against Ab-induced cytotoxicity in
SH-SY5Y cells and mouse primary cortical cells. The complexes
generated by Ma and coworkers thus provide an early demon-
stration that it is possible to create theranostic systems, namely
agents able to inhibit (therapeutic) and monitor (diagnostic) Ab
peptide formation via luminescence.
Ruthenium (Ru2+)
As true for Ir-systems, ruthenium (Ru2+) complexes have found
extensive use in bioimaging applications. Recent efforts
have been devoted to exploring cellular imaging and sensing
applications wherein octahedral dipyridophenazine (dppz)
Ru2+ complexes are used as molecular ‘‘light-switches’’. For
instance, Marti and co-workers reported a Ru2+-based complex
[Ru(bpy)2(dppz)]
2+ (bpy = bipyridyl) that undergoes a photo-
switching process in the presence of Ab aggregates (Fig. 30).42
Specifically, upon binding to Ab fibrils, [Ru(bpy)2(dppz)]
2+
displayed a 50-fold increase in luminescence intensity (‘‘turn-on’’)
as compared to the free Ru complex in aqueous solution. In the
presence of monomeric Ab only a minimal increase in lumines-
cence intensity was observed. By exploiting the long emission
lifetimes of [Ru(bpy)2(dppz)]
2+, time-resolved experiments enabled
the monitoring of Ab binding within a fluorescent environment.
This work demonstrates the potential to overcome a major
limitation associated with most current ThT-Ab inhibition
screening assays, since it shows that it is possible to use an
appropriately chosen metal complex to screen potential Ab
inhibitors with inherent fluorescent properties.
PD is often characterized by the abnormal accumulation
of Lewy body protein aggregates comprised primarily of the
alpha-synuclein (aS) peptide. The role of aS in the development
of PD has been studied with data showing a strong correlation
between aS misfolding and aggregation and the progression of
PD pathogenesis. However, the direct cause of aS misfolding
and aggregation as well as the role of aS accumulation in the
development of PD has yet to be elucidated. The development
of an effective imaging agent that allows aS misfolding and
Fig. 29 Optimised octahedral cyclometallated iridium (Ir3+) phenyl-imidazo-phen-based complexes (5–7) developed by Ma and co-workers for the
simultaneous detection of Ab peptide and inhibition of Ab plaque formation.
Fig. 30 (A) Ru2+-Based dipyridophenazine (dppz) complex reported by Marti and co-workers. (B) [Ru(bpy)2(dppz)]
2+ time-gated assay for the monitoring
of Ab fibril formation in a fluorescent medium (rhodamine B). Reprinted (adapted) with permission from (J. Am. Chem. Soc., 2011, 133, 11121–11123).
Copyright (2019) American Chemical Society.
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aggregation progression to be monitored readily is thus viewed
as being highly desirable.
Building on their earlier work summarised above, Marti
and co-workers recently reported a 1,10-phenathroline (phen)
supported Ru complex, [Ru(phen)2dppz]
2+ and showed it could
be used to monitor aS fibrillization.43 Upon binding to aS fibrils,
an 18-fold increase in luminescence emission intensity was observed
with a remarkable selectivity. [Ru(phen)2dppz]
2+ also displayed
good cell permeability with low toxicity in human neuroglioma
H4 cells, as well as an ability to distinguish between healthy
cells and cells overexpressing aS (H4-MG-132) (Fig. 31).
The Ru2+ complexes prepared by Marti and associates provide
an excellent demonstration of an optical imaging agent. They
retain the benefits of the ThT displacement assay currently used
in AD research in that they are amenable to use in the high-
throughput screening of potential therapeutics targeting aS
fibrillization in PD. However, they may be employed under
conditions complicated by the presence of a fluorescent back-
ground. In addition, these luminescent-based imaging systems
may allow the general monitoring of protein aggregation in vitro
and do so with high spatial and temporal resolution.
Rhenium (Re+)
Rhenium (Re+) tricarbonyl bipyridine [Re(N^N)(CO)3X]
n+
[X = anionic (n = 0) or neutral (n = 1)] complexes have found
extensive use in bioimaging applications.39 As true for the
[Ru(bpy)2(dppz)]
2+ complexes discussed immediately above,
[Re(dppz)(CO)3]
+ also displays light-switching properties and is
capable of detecting biologically important species. In continua-
tion of their efforts on luminescent transition metal probes,
Marti and co-workers reported that [Re(CO)3(dppz)(Py)]
+ could be
used to effect the luminescent-based detection of Ab aggregates
(Fig. 32).44 [Re(CO)3(dppz)(Py)]
+ was shown to be non-emissive
in aqueous buffer. However, upon exposure to fibrillar Ab, an
instantaneous 18-fold increase in luminescence emission
intensity was observed. Upon light irradiation for 6000 s in
the presence of oxygen, the Ab peptide underwent oxidation.
The resultant modifications of the Ab peptide induced an
unprecedented second light-switching event with an attendant
105-fold increase in luminescence emission intensity. As used
by Marti and coworkers, [Re(CO)3(dppz)(Py)]
+ provides an
elegant demonstration of a luminescent-based imaging system
that may be used to monitor Ab plaque formation and to obtain
insights into the local environment within the Ab plaque that
results from oxidation.
More recently, Pigge and co-workers reported a series of
oligothiophene benzothiazole-based tetraarylethylene (TAE)
Re(CO)3 complexes (8–13) and showed that these systems were
capable of monitoring Ab aggregate formation in real time.45
The benzothiazole TAE chelating ligands used in this study
contain a different number of thiophene units, a variation
that serves to modulate the photophysical properties and
the binding affinities toward Ab fibrils. In aqueous solution,
complexes 8–10 displayed minimal luminescence emission
intensity (Fig. 33). However, in the presence of Ab aggregates,
a significant increase in the luminescence emission intensity
was observed. Complex 8 displayed the smallest response in
the presence of aggregated Ab fibrils (B13-fold), complex 9
exhibited the largest response with a 34-fold increase in lumi-
nescence intensity, and complex 10 demonstrated the largest
Stokes shift (105 nm) with a red-shifted emission in the NIR
region (lem = 641 nm). Complex 9 was also evaluated against
Fig. 31 [Ru(phen)2dppz]
2+ complex used by Marti and co-workers to
monitor in real-time aS fibrillization in human neuroglioma cells (H4).
Reprinted (adapted) with permission from (J. Am. Chem. Soc., 2012, 134,
20776–20782). Copyright (2019) American Chemical Society.
Fig. 32 [Re(CO)3(dppz)(Py)]
+ complex Marti and co-workers that allows
for the luminescence detection of Ab aggregates. As noted in the main
text, this system undergoes an unprecedented second light-switching
event upon light irradiation.
Fig. 33 Oligothiophene benzothiazole-based tetraarylethylene (TAE)
Re(CO)3 complexes (8–10) reported by Pigge and co-workers.
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other bio-macromolecules and displayed excellent selectivity
towards the Ab peptide.
To confirm further the structural importance of both thio-
phene and benzothiazole functionalities, complexes 11–13 were
synthesised (Fig. 34). In the case of complex 11, each (oligo)-
thiophene moiety was replaced by a phenyl ring. In 12 and 13 the
bis(bithiophene) units were retained, but the benzothiazole core was
replaced by ones based on bis(2-pyridyl) or bis(2-quinolyl)Re(CO)3
subunits, respectively. As anticipated, complexes 11–13 displayed
only a modest increase in emission intensity in the presence of Ab
fibrils. The high binding affinities and desirable photophysical
properties of the oligothiophene benzothiazole-based Re complexes
8–10 supports the contention that these systems may have a role to
play as fluorescent Ab probes, perhaps as an alternative to ThT.
Additionally, the fact that this class of complexes is easy to modify
leads us to suggest that they could inspire the development of new
second-generation TAE-based diagnostic tools for investigating
protein aggregation in AD and other neurological diseases.
Lanthanide-based imaging agents
Trivalent lanthanide ions (Ln3+) display unique intrinsic lumi-
nescence properties that arise from the f–f electron transitions.
However, as transitions occurring within the same orbitals
(4f–4f) are Laporte forbidden, Ln3+ ions display low absorption
coefficients. This complicates the efficient harnessing of their
luminescence properties. Free Ln3+ ions are also toxic, which
makes them unsuitable for bioimaging applications per se. To
circumvent toxicity and their poor absorptivity, Ln3+ ions
are typically chelated by polyanionic macrocycles, such as
DOTA and DTPA, and functionalised with various organic
chromophores for use as light excitation ‘‘antennas’’. These
‘‘antennas’’ enable efficient Ln-based luminescence proceeding
via excitation of the organic antennas to their respective
S1 excited states, followed by intersystem crossing to their
T1 states. Subsequent intramolecular charge transfer populates
the excited state of the Ln3+ ion; relaxation of the ion to the
ground state then produces a unique fingerprint emission
characteristic of the Ln3+ ion in question (Fig. 35).
Unlike transition metal complexes, lanthanide-based emis-
sions are not significantly affected by the surrounding environ-
ment or ligands. Indeed, even under widely different conditions,
almost no variation is observed in the emission/excitation wave-
lengths of the Ln3+ ions. The lack of such interactions is attributed
to the valence 4f orbitals being core-like with shielding from
Fig. 34 Benzothiazole-based tetraarylethylene (TAE) Re(CO)3 complexes
(11–13).
Fig. 35 (A) Sensitisation through a chromophore generally leads to more intense emission in comparison to direct excitation of the Ln3+ ion. (B)
Simplified Jablonski diagram illustrating the sensitisation of Ln3+ ions, in this case Tb3+. (C) A typical chromophore-sensitised Tb3+ emission spectrum
(solid green trace), showing the large Stokes shift relative to the chromophore excitation spectra (dashed blue line) that is typically observed.
Tutorial Review Chem Soc Rev
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 3
0 
M
ar
ch
 2
02
0.
 D
ow
nl
oa
de
d 
on
 7
/8
/2
02
0 
1:
39
:2
3 
PM
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
2910 | Chem. Soc. Rev., 2020, 49, 2886--2915 This journal is©The Royal Society of Chemistry 2020
chemical bonding by the populated 5s and 5p orbitals. This
feature, coupled with the spin and Laporte forbidden nature of
these electronic transitions, yields long luminescence lifetimes in
the micro- to millisecond range. Luminescent-based lanthanide
imaging agents have thus found utility in time-gated or time-
resolved live-cell and in vivo imaging. A significant advantage of
these lanthanide based optical imaging agents is that varying the
Ln3+ centre yields only minor changes in the chemical properties
enabling multimodal and multiplexed applications. However,
since each Ln3+ ion gives rise to unique luminescent features, in
principle it is possible to generate several similar imaging agents
based on the same organic framework.
While the wavelengths of Ln3+ transitions are typically fixed,
it is possible to modulate the emission intensity and, for some
of the ions, the ratio between different emission bands. To
date, three main determinants have been used to modulate the
luminescence signal of lanthanide-based optical imaging agents
for the detection of disease related biomarkers; these are:
 Varying q
 Adjusting the antenna–Ln3+ ion distance
 Modulating the antenna excited state
Varying q, number of bound water molecules, influences the
emission intensity, luminescence lifetime, and spectral form of
otherwise similar Ln complexes. This influence is due to
quenching of the excited state(s) caused by the O–H bond
vibrations. Design considerations used to adjust the extent of
sensitization produced by the antenna stem from an apprecia-
tion that the energy transfer from the triplet excited state (T1) of
the antenna to the metal ion is both distance and energy
dependent. Current systems have focused on altering the Ln-
antenna distance through chemical reactions or binding events.
Finally, modulation of the antenna excited state has been
achieved. Typically, this has been done by exploiting aqueous-
based chemoselective reactions with kinetics that are fast even in
complex biological environments to achieve chemical modifica-
tion to the antenna. This latter approach is particularly attractive
in the context of designing agents for the selective detection of
neurodegenerative specific analytes.
For the development of molecular lanthanide-based optical
imaging agents, three major factors need to be taken into
consideration: The Ln3+ ion itself, the photophysical and chemical
properties of the chelating ligand, and the photophysical features
of the organic-based sensitising antenna. Historically, applica-
tions in lanthanide-sensing agents have utilized europium (Eu3+)
and terbium (Tb3+), owing to their high intrinsic quantum yields,
long-luminescence lifetimes, and emission bands that fall in the
visible region. Recent efforts have also focused on neodymium
(Nd3+) and ytterbium (Yb3+) as near IR-emitting analogues. For
additional and extensive overviews on the use of lanthanide-
based imaging agents for general bioimaging applications,
the reader is directed to two excellent reviews by Meade and
Huang.23,38
Se´ne`que and co-workers recently reported a responsive
system that combines functional readout with multiplexing
capabilities. In this system, the authors relied on a bio-
inspired zinc finger peptide strategy for the selective lumines-
cent detection of Zn2+ ions through the modulation of the
antenna–Ln3+ ion distance (Fig. 36).46 They exploited the ten-
dency of bba zinc finger (ZF) peptides to change conformation
and fold in the presence of Zn2+ over other biologically relevant
metal ions. Four different bba zinc finger (ZF) peptides contain-
ing a conjugated Ln3+–DOTA complex and a sensitizing
antenna were prepared. Chelation of the Zn2+ cation resulted
in a conformational change, basically a folding to the system,
which served to decrease the distance between the small
molecule sensitizer and the reporter Ln3+–DOTA complex lead-
ing to an increase in the luminescence intensity.
Initial efforts were focused on a Tb3+-based peptide
(LZF1Trp|Tb) with a tryptophan antenna. This framework yielded
a time-delayed 8.5-fold enhancement in the emission intensity
in the presence of Zn2+ (1 equiv.). Luminescence lifetime
measurements revealed no change in the number of water
molecules within the Tb3+ coordination sphere, providing
support for the contention that the observed luminescence
enhancement was due to zinc-induced peptide folding. In a
similar vein, a neodymium (Nd3+) LZF1NBD|Nd probe was developed
Fig. 36 Binding of Zn2+ results in a conformation change of the zinc-finger peptides, which bring the chromophore antenna spatially closer to the Ln3+
ion, resulting in an increase in Ln3+ emission intensity. Reprinted (adapted) with permission from (Chem. – Eur. J., 2017, 23, 10992–10996). Copyright
(2019) John Wiley and Sons.
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that gave rise to a NIR emission upon exposure to the Zn2+
cation in aqueous conditions.
Multimodal systems that combine the emissive Tb3+/Eu3+
ions with the MRI active Gd3+ cation have been studied in an
effort to generate imaging agents that permit both luminescence
and MRI readouts.47 To´th and co-workers recently employed this
bimodal approach in an effort to image neurotransmitter signal-
ling in neurodegenerative disease models.48 In particular, a
Gd-DO3A complex functionalised with a triazacrown ether
(Gd-DO3A-3AC) was prepared. This framework enabled the ditopic
binding of the excitatory neurotransmitter L-glutamate (L-Glu),
comprised of cationic ammonium (–NH3
+) and negatively charged
carboxylate (–COO) groups (Fig. 37). The coordinatively unsatu-
rated Gd3+ metal centre (positively charged) provided a binding
site for the carboxylate functionality (negatively charged), while
the appended triazacrown ether unit enabled binding of the
Fig. 37 (A) Glutamate-responsive contrast agents. Here Ln = Gd3+, Eu3+, Yb3+, Nd3+. (B) The chemical structure of glutamate is shown along with that of
two common neurotransmitters, dopamine and serotonin. (C) Longitudinal relaxivity change seen for the Gd3+ complex as a function of increasing
glutamate (Glu) concentration. (D) Excitation and emission spectra of the Nd3+ and Yb3+ analogues.
Table 3 General characteristics of the imaging modalities presented in this review. Combination of the various approaches may alleviate some of the
limitations associated with employing each technique individually. MRI image adapted with permission from (Schizophr. Bull., 2008, 34, 595–604). PET/
SPECT image adapted with permission from (J. Med. Chem., 2012, 55, 2279–2286). Luminescent image adapted with permission from (J. Am. Chem.
Soc., 2012, 134, 20776–20782)
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cationic –NH3
+ group. The dual coordination of Gd-DO3A-3AC
rendered it capable of discriminating zwitterionic neurotrans-
mitters from monoamine neurotransmitter (e.g., serotonin vs.
noradrenaline). Upon coordination of the appropriate neuro-
transmitter, a marked change in relaxivity was observed. This
was believed to arise from a decrease in the hydration number
(q). Gd-DO3A-3AC was also used to monitor neural activity in
ex vivo mouse brain slices by MRI.
More recently, Toth and co-workers extended this design
strategy by attaching a benzophenone chromophore to the
lanthanide ligand site.49 Incorporation of this flat aromatic
substituent led to an increased interaction with albumin
causing an enhancement in the overall relaxivity. Unfortunately,
this came with an overall decrease in the neurotransmitter
response. On the other hand, the presence of the benzophenone
chromophore allowed for efficient sensitisation of Eu3+, Nd3+,
and Yb3+, thus paving the way towards both the visible and near-
infrared (NIR) detection of neurotransmitters. These additional
studies by Toth and associates provide an illustrative example of
the multimodal capabilities possible by creating a system that
can function with different Ln3+ ions. It is to be noted, however,
that the instability (i.e., photoreactivity) of these first generation
systems have precluded their use in more advanced application
scenarios.
The efforts with Ln3+ luminescent systems summarised
above have provided initial support for the notion that such
systems may have utility in the context of elucidating the
biochemical mechanisms associated with various disease
states. However, this area remains in its infancy in terms of
potential applications involving neurodegenerative disorders.
Conclusion and future perspectives
As shown throughout this review, PET/SPECT, MRI and lumi-
nescence are non-invasive molecular imaging techniques that
show particular promise in terms of visualising various patho-
logical biomarkers that may play a role in the development of
neurodegenerative diseases. We have to highlight the fact that
each metal-based imaging technique has a set of unique
advantages and disadvantages (Table 3). For example, metal
complex luminescence-based imaging agents offer a method to
visualise specific biomarkers with high sensitivity, specificity,
and spatial resolution at the cellular/subcellular level (i.e.,
mitochondria). On the other hand, they generally suffer from
poor tissue penetration leading to limited in vitro and in vivo
applications. In contrast, PET/SPECT-based imaging agents
have been used extensively to monitor various metabolic/
physiological processes and disease related biomarkers with
high sensitivity (pM/nM range). However, PET/SPECT provide
images with relatively poor resolution and require the use of
ionising radiation. On the other hand, small molecule MRI
imaging agents have been widely used to effect clinical diag-
noses and in the context of research related to neurodegenera-
tive disease. Various small molecule MRI imaging agents have
been used to visualise various anatomical architects and
pathological biomarkers with high spatial resolution with
nearly unlimited depth penetration. However, MRI-based
imaging approaches are typically hampered by relatively poor
sensitivity (in the mM range); this makes the detection of
biologically important species (i.e., DAT) present at nM con-
centrations in vivo difficult, if not impossible.
Increasingly, researchers in the field are coming to appreci-
ate that no single imaging modality will typically suffice to
obtain all the necessary information needed for a clinical
diagnosis or for understanding of a specific pathological
process. Dedicated efforts in a number of laboratories are thus
being made to combine various imaging methods to develop
so-called multimodal approaches. For instance, PET/SPECT is
being used in conjunction with MRI in an effort to overcome
the limitations of each imaging modality so as to unravel more
effectively the determinants of various disease states.50 We
anticipate a continued growth in metal-based imaging agents,
particularly multimodal systems, that will permit a deeper
understanding of neurodegenerative disease and its underlying
causes. Ultimately, the knowledge gained from the design and
study of metal-based imaging agents is expected to translate
into new therapeutics and cures for these frightening and
debilitating disorders.
Abbreviations
aS Alpha-synuclein
b+ Beta positive decay
b Beta minus decay
mM Micrometre
g Gamma ray emission
11C Carbon-11
61Cu Copper-61
62Cu Copper-62
64Cu Copper-64
18F Fluorine-18
68Ga Gallium-68
123I Iodine-123
99Mo Molybdenum-99
89Zr Zirconium-89
L-Glu Glutamic acid
tm Mean residence lifetime
tr Rotational correlation time
Ab Amyloid beta
AD Alzheimer’s disease
Ag Silver
AgCl Silver chloride
Au+ Gold ion
ALS Amyotrophic lateral sclerosis
Atsm Diacetyl-bis(N4-methylthiosemicarbazone)
BBB Blood brain barrier
bDHC Bis(dihydroxy)curcumin
BAPTA 1,2-Bis(o-aminophenoxy)ethane-N,N,N0,N0-tetra-
acetic acid
BOLD Blood-oxygenation level dependent
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BPy Bipyridyl
Bzq Benzoquinoline
CA Contrast agent
Ca2+ Calcium ion
CEST Chemical exchange saturation transfer
CN Coordination number
CNS Central nervous system
CO Carbon monoxide
Cp Cyclopentyl
Cu+/2+ Copper ion
CT Computer tomography
DAC Diacetylcurcumin
DAT Dopamine active transporter
DFO Desferrioxamine B
DO3A 1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic
acid
DOTA 1,4,7,10-Tetraazacyclododecane-1,4,7,10-
tetraacetic acid
DOPTA 1,4,7-Tris-(carboxymethyl)-1,4,7,10-
tetraazacyclododecane
dppz Dipyridophenazine
EC Electron capture
EDTA Ethylenediaminetetraacetic acid
Eu Europium
FDA Food and drug administration
Fe2+/3+ Iron
fMRI Functional magnetic resonance imaging
GABA g-Aminobutyric acid
GAD Glutamate decarboxylase
Gd3+ Gadolinium ion
Ge Germanium
GFP Green fluorescent protein
gtsm Glyoxal-bis(N4-methyl-3-thiosemicarbazonato)
h Hours
Hb Haemoglobin
HD Huntington’s disease
ID g1 Injected does per gram tissue
IL Intraligand
In3+ Indium ion
Ir3+ Iridium ion
K+ Potassium ion
Kd Dissociation constant
keV Kiloelectron volts
Ki Inhibition constant
L Ligand
LCIO Lipid coated iron oxide nanoparticles
LLCT Ligand-to-ligand charge-transfer
LMMCT Ligand-to-metal–metal charge-transfer
LMCT Ligand-to-metal charge-transfer
Ln3+ Lanthanide ion
Lys Lysine
mAb Monoclonal antibody
MaCaReNa Magnetic calcium-responsive nanoparticles
MeV Megaelectron volt
MEMRI Manganese-enhanced magnetic resonance
imaging
mM Millimolar
MMLCT Metal–metal-to-ligand charge-transfer
MLCT Metal-to-ligand charge-transfer
MLLCT Metal-to-ligand–ligand charge-transfer
Mn2+/3+ Manganese ion
MRI Magnetic resonance imaging
Min Minute
ms Millisecond
mV MilliVolt
Nd3+ Neodymium ion
nM Nanomolar
NOTA 1,4,7-Triazacyclononane-1,4,7-trisacetic acid
ns Nanosecond
O2 Oxygen
O2
 Superoxide anion
Os2+ Osmium ion
PCTA 3,6,9,15-Tetraazabicyclo[9.3.1]-pentadeca-
1(15),11,13-triene-3,6,9-triacetic acid
PD Parkinson’s disease
PDA Phenylenediamido
PEG Polyethylene glycol
PET Positron emission tomography
Pt2+ Platinum ion
Phen 1,10-Phenathroline
PiB Pittsburgh compound B
PLIM Phosphorescence lifetime imaging
Phq 2-Phenylquinoline
Ppy 2-Phenylpyridine
Py Pyridine
pM Picomolar
ps Picoseconds
Py Pyridine
q Average number of water molecules bound
directly to the paramagnetic metal centre
r1/2 Relaxivity
Re+ Rhenium ion
Rh3+ Rhodium ion
RF Radiofrequency
Ru2+ Ruthenium ion
SPECT Single photon emission computed tomography
SPION Superparamagnetic iron oxide nanoparticles
USPIO Ultra-small superparamagnetic iron oxide
nanoparticles
t1/2 Half-life
T Tesla
T1 Longitudinal time constant
T2 Transverse time constant
TAE Tetraarylethylene
Tb3+ Terbium ion
99mTc Technetium-99m
Tg Transgenic
TGL Time-gated luminescence
ThT Thioflavin T
Yb3+ Ytterbium ion
Zn Zinc
89Zr Zirconium-89
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